Neurology News

ORLANDO, Fla.--(BUSINESS WIRE)--Imaginostics, Inc. today announced that it has received a Letter of Support from Siemens Healthineers in connection with ongoing exploratory discussions regarding potential collaboration in quantitative MRI and imaging biomarkers. As part of these discussions, Imaginostics and Siemens Healthineers intend to continue dialogue concerning potential technical and commercial pathways for Imaginostics’ envisioned ImagiView™ and ImagiSight™ offerings and their potential...

AUSTIN, Texas--(BUSINESS WIRE)--IntraBio Inc. today announced the submission of a supplemental New Drug Application (sNDA) to the U.S. Food and Drug Administration (FDA) for levacetylleucine for the treatment of Ataxia-Telangiectasia (A-T), a rare, progressive, inherited neurodegenerative disorder. This submission represents the first regulatory application submitted to the U.S. Food and Drug Administration seeking approval of a therapy for the treatment of Ataxia-Telangiectasia. The sNDA seeks...

MILAN & MORRISTOWN, N.J.--(BUSINESS WIRE)--Newron Pharmaceuticals S.p.A. (“Newron”) (SIX: NWRN, XETRA: NP5), a biopharmaceutical company focused on the development of novel therapies for patients with diseases of the central and peripheral nervous system, today announced that it will take part in a workshop and present three posters at the upcoming SIRS 2026 Annual Congress taking place March 25-29, 2026, at the exhibition and congress area Firenze Fiera in Florence, Italy. Workshop Wednesday,...

PARIS--(BUSINESS WIRE)--Regulatory News: The 15-20 National Hospital (l’Hôpital national des 15-20) in Paris and GenSight Biologics (Euronext: SIGHT, ISIN: FR0013183985, PEA-PME eligible), a biopharma company focused on developing and commercializing innovative gene therapies for retinal neurodegenerative diseases and central nervous system disorders, today announced that the first patients have been treated in the French Named Patient Early Access Program (AAC) for GS010/LUMEVOQ®.1 The REVISE...

AUSTIN, Texas--(BUSINESS WIRE)--Today, Bonterra, along with leaders across military, healthcare, technology, and nonprofit sectors announced the launch of HEADS UP VET, a national coalition led by Veterans Collaborative, a first-of-its-kind public-private-community partnership aimed at addressing the impact of undiagnosed head injuries and reducing suicide risk among U.S. veterans. Research has found that veterans diagnosed with traumatic brain injury face a 56% higher risk of suicide compared...

WALTHAM, Mass.--(BUSINESS WIRE)--As the demand for quality, evidence-based medical research content continues to grow, Wolters Kluwer Health has renewed and expanded its relationship with the American Heart Association. Wolters Kluwer will now publish the Open Access journal Stroke: Vascular and Interventional Neurology alongside the flagship journals Circulation and Stroke, for a total of twelve American Heart Association journal titles. Trusted medical research from the leading cardiology voi...

MOUNTAIN VIEW, Calif.--(BUSINESS WIRE)--Aditxt, Inc. (Nasdaq: ADTX) (“Aditxt” or the “Company”), a social innovation platform accelerating promising health innovations, today announced the appointment of Jeff Busch as Chief Executive Officer of its subsidiary, Ignite Proteomics, LLC (“Ignite” or “Ignite Proteomics”). Ignite Proteomics was recently acquired by Aditxt and operates a commercial-stage precision oncology platform designed to guide cancer therapy selection through functional protein...

ST. LOUIS--(BUSINESS WIRE)--C2N Diagnostics, LLC (“C2N”), a specialty diagnostics company with a vision to bring Clarity Through Innovation®, highlighted the first use of its eMTBR-tau243 plasma assay in a Phase 3 dataset (Evoke/Evoke+), reflecting ongoing interest in tau-related signals within Alzheimer’s disease research. The data were presented at the AD/PD™ 2026 Alzheimer's & Parkinson's Diseases Conference during the Evoke/Evoke+ Trial Symposium, which focused on Evoke and Evoke+ cereb...

MILAN & MORRISTOWN, N.J.--(BUSINESS WIRE)--Newron announces agreement with the European Investment Bank (EIB) to extend the near-term tranche repayment dates of its 2018 Finance Contract...

ZURICH--(BUSINESS WIRE)--AL-S Pharma AG, a clinical-stage biotechnology company discovering and developing human antibodies that target misfolded proteins implicated in amyotrophic lateral sclerosis (ALS), today announced the presentation of new clinical data from the global Phase 2 clinical trial (AP-101-02) evaluating the company’s lead program, AP-101, in patients with ALS. AP-101 is an investigational human-derived antibody directed against misfolded superoxide dismutase 1 (SOD1). AP-101 is...